Severe Asthma Drugs Market is segmented By Current Therapies (Inhaled Corticosteroids, Biologic Therapies, Bronchodilators), By Biologic Therapies (IL-5 Inhibitors, TSLP ....
Market Size in USD
CAGR6.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.1% |
Market Concentration | High |
Major Players | GlaxoSmithKline (GSK), Biosion, Bio-Thera Solutions, Sanofi, AstraZeneca |
The Global Severe Asthma Drugs Market is estimated to be valued at USD 24.51 Bn in 2024 and is expected to reach USD 40.66 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. Several key factors such as the growing prevalence of asthma worldwide and rising pollution levels are expected to drive the demand for severe asthma drugs during the forecast period.
The Severe Asthma Drugs Market is expected to witness significant growth over the next few years. The market is currently dominated by biologics and there is high demand for novel drug molecules that are more effective and have fewer side effects. Many pharmaceutical companies are actively involved in research & development to develop advanced therapeutics, which is likely to intensify competition in the market.